Physician profile
Eli Kim
NPI 1861727802
$3,191.02
in general payments reported to CMS, 2019-2025
29 companies · $486 in 2025
The $486 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $400 · 2020: $216 · 2021: $473 · 2022: $735 · 2023: $382 · 2024: $498 · 2025: $486.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,272 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,271.66 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $529.88 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $433.31 | 2019-2025 | |
| Lilly USA, LLC | $387.08 | 2019-2024 | Taltz, Olumiant, Ebglyss |
| Janssen Biotech, INC. | $383.67 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Mayne Pharma Commercial LLC | $199.30 | 2020-2024 | |
| Regeneron Healthcare Solutions, INC. | $172.66 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $165.02 | 2020-2025 | Ilumya |
| Kerecis Limited | $104.02 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Genzyme Corporation | $98.64 | 2021-2023 | |
| E.R. Squibb & Sons, L.L.C. | $84.65 | 2022-2024 | Sotyktu |
| Galderma Laboratories, L.P. | $59.17 | 2020-2023 | |
| Biofrontera INC. | $58.66 | 2024-2025 | Xepi, Bf-Rhodoled, Ameluz |
| Mimedx Group, INC. | $58.10 | 2024-2025 | |
| Almirall LLC | $58.07 | 2019-2024 | Seysara |
| Ucb, INC. | $47.13 | 2019-2025 | Bimzelx |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $46.42 | 2023-2025 | |
| Revance Therapeutics, INC. | $39.58 | 2024 | Daxxify |
| Merz North America, INC. | $36.98 | 2019-2025 | |
| Incyte Corporation | $35.97 | 2022-2024 | Opzelura |
| Dermavant Sciences, INC. | $31.87 | 2022 | |
| Amgen INC. | $27.63 | 2023 | Otezla |
| Verrica Pharmaceuticals INC. | $22.98 | 2024 | Ycanth |
| Organon LLC | $22.94 | 2025 | |
| Mallinckrodt Hospital Products INC. | $22.34 | 2025 | Acthar |
| Mission Pharmacal Company | $14.14 | 2019 | |
| Genentech USA, INC. | $13.58 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $13.44 | 2023 | Seglentis |
| Smith+Nephew, INC. | $12.67 | 2021 | |
| Aclaris Therapeutics, INC. | $11.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eli Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.